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Abstract
Background: Corticotropin-releasing hormone (CRH) plays a central role in regulating the 
secretion of cortisol which controls a wide range of biological processes. Fetuses overexposed to 
cortisol have increased risks of disease in later life. DNA methylation may be the underlying 
association between prenatal cortisol exposure and health effects. We investigated associations 
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between maternal CRH levels and epigenome-wide DNA methylation of cord blood in offsprings 
and evaluated whether these associations persisted into mid-childhood.
Methods: We investigated mother-child pairs enrolled in the prospective Project Viva pre-birth 
cohort. We measured DNA methylation in 257 umbilical cord blood samples using the 
HumanMethylation450 Bead Chip. We tested associations of maternal CRH concentration with 
cord blood cells DNA methylation, adjusting the model for maternal age at enrollment, education, 
maternal race/ethnicity, pre-pregnancy body mass index, parity, gestational age at delivery, child 
sex, and cell-type composition in cord blood. We further examined the persistence of associations 
between maternal CRH levels and DNA methylation in children’s blood cells collected at mid-
childhood (N = 239, age: 6.7–10.3 years) additionally adjusting for the children’s age at blood 
drawn.
Results: Maternal CRH levels are associated with DNA methylation variability in cord blood 
cells at 96 individual CpG sites (False Discovery Rate < 0.05). Among the 96 CpG sites, we 
identified 3 CpGs located near the LEP gene. Regional analyses confirmed the association 
between maternal CRH and DNA methylation near LEP. Moreover, higher maternal CRH levels 
were associated with higher blood-cell DNA methylation of the promoter region of LEP in mid-
childhood (P < 0.05, β = 0.64, SE = 0.30).
Conclusion: In our cohort, maternal CRH was associated with DNA methylation levels in 
newborns at multiple loci, notably in the LEP gene promoter. The association between maternal 
CRH and LEP DNA methylation levels persisted into mid-childhood.
Keywords
corticotropin-releasing hormone; DNA methylation; cord blood; childhood; LEP
Background
Corticotropin-releasing hormone (CRH), a peptide that is synthesized and released from the 
hypothalamus, is the main central regulator in the hypothalamic-pituitary-adrenal (HPA) axis 
1
. During pregnancy, maternal CRH in the bloodstream is largely derived from placenta 
secretion and triggers secretion of maternal cortisol that activates more release of CRH from 
placenta 2. This feed-forward loop leads to an increase in maternal CRH 3 and a two- to 
four-fold higher maternal cortisol secretion in normal pregnancy 4. Placental enzymes only 
partially inactivate maternal cortisol, and a large amount of active cortisol are passed to the 
fetus 5. Fetal cortisol levels are positively correlated with maternal cortisol levels 6, and thus, 
maternal plasma CRH levels during pregnancy reflect the intensity of fetal cortisol exposure.
Fetal cortisol exposure leads to both beneficial and detrimental consequences: cortisol is 
necessary for fetal organ maturation (e.g., lung, kidney, heart) 7; however, in humans, 
excessively high levels of cortisol have been associated with preterm birth 6, small for 
gestational age 8, HPA axis dysfunction 9, and with obesity 10 and metabolic syndromes 11 
later in life. Animal studies also showed adverse effects of excess cortisol that prenatal 
synthetic glucocorticoids treatments modify HPA axis function and increase the risk of 
obesity and diabetes in the offspring 12–15. These studies support the hypothesis that prenatal 
cortisol exposure – regulated by maternal CRH – contributes to the fetal growth and long-
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term development. Additionally, previous studies in our cohort have demonstrated that 
higher maternal CRH is associated with a higher risk of central adiposity and adiponectin 
levels in early childhood 16, but lower BMI in offspring 10.
DNA methylation is regarded as an important mechanism by which early life exposures may 
lead to long-term programming, sometimes leading to structural and functional changes that 
can persist later in life and have long-term effects 17,18. Both human and animal studies 
found DNA methylation modifications at HPA-axis genes (e.g., NR3C1, NR3C2, CRH, 
POMC, HSD11B2β) and modified HPA-axis function in the offspring whose mother were 
treated with synthetic glucocorticoids during gestation19,20. However, no prior study 
investigated the associations between maternal CRH and offspring DNA methylation in 
humans using an epigenome-wide approach.
We hypothesized that maternal CRH is associated with DNA methylation levels in cord 
blood, and some of the associations would last into mid-childhood. We investigated 
associations between maternal CRH levels and DNA methylation in cord blood cells in 
>450,000 sites across the genome and evaluated whether these associations persist into mid-
childhood.
Methods
Study population
We recruited pregnant women into Project Viva during their first prenatal visit (initially 2128 
mother-child pairs at median 9.9 gestation weeks) at eastern Massachusetts Atrius Harvard 
Vanguard Medical Associates practices, between 1999 and 2002. Details of this prospective 
pre-birth cohort have been described previously 21. We included 257 mother-child pairs in 
the cord blood analysis, and we included 239 mother-child pairs in mid-childhood (range: 
6.7–10.3 years) DNA methylation analysis, according to availability of maternal CHR 
measurement and DNA methylation data that passed our sample quality control (Figure S1). 
We analyzed 134 mother-child pairs who had all data available at both time-points (Figure 
S2). All mothers provided written informed consent. The research was approved by the 
Institutional Review Board at Harvard Pilgrim Health Care.
Maternal corticotropin-releasing hormone (CRH) measurement
Collection of maternal blood samples, CRH measurement and data processing in this cohort 
has been previously described 22. Briefly, we assayed for CRH with an RIA assay kit 
(Peninsula Laboratories Inc., San Carlos, CA) following the manufacturer’s instructions. To 
eliminate bias introduced by batch effect and gestational age at CRH test, we conducted a 
two-stage correction for the original CRH measurements. In the first stage, we adjusted 
CRH levels for batch effects (adjusted CRH = e(ln(original CRH) + 0.48)). In the second stage, 
we additionally adjusted CRH levels for gestational age at maternal blood drawn 10 (Figure 
S3). Henceforward, maternal CRH refers to the fully two-stage adjusted maternal CRH.
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DNA methylation assessment
Collection, processing, and storage of cord blood samples and children’s peripheral blood in 
mid-childhood has been previously described 23. Trained laboratory staff extracted DNA 
from blood samples using commercially available PureGene Kits (Fisher, catalog #: A407–
4, A416–4; Qiagen, catalog #: 158908, 158912, 158924) and conducted sodium bisulfite 
conversion on DNA using the EZ DNA Methylation-Gold Kit (Zymo Research, Irvine, CA). 
We measured DNA methylation across the genome using the Infinium 
HumanMethylation450 BeadChip (Illumina, San Diego, CA) following standard 
manufacturer’s protocols. To reduce the influence of batch effect and to ensure the balance 
of sex, samples were randomly allocated to assay chips, and chips were randomly assigned 
to plates.
Quality control
The DNA methylation data processing is as previously described 23. We excluded 65 actual 
SNPs, 11648 probes on sex chromosomes, 2994 non-CpG probes, 8715 probes with poor 
detection (P > 0.05) for more than 1% samples, 27951 cross-reactive probes 24 and 99224 
SNP-containing probes (Figure S4). We included a total of 334980 out of 485577 CpGs in 
the analysis. For each CpG site, methylation level is represented by the average β-value = M/ 
(M+ U+ ε), where M and U represent the average fluorescence intensity corresponding to 
the methylated and unmethylated target CpG while ε usually equals 100. The average β-
value, ranging between 0 and 1, is interpreted as the proportion CpG methylated at each site. 
β-scale DNA methylation levels were logit transformed to M-values (M = log2(β) – log2(1 – 
β)) for a distribution that was more appropriate for the analysis of DNA methylation. The 
batch effect was not associated with the first 30 principal components of DNA methylation 
variance in cord blood (Figure S5) and children’s blood (plot not shown) after we performed 
the batch effect adjustment using ComBat approach, which indicated adequate removal of 
batch effects. We used ComBat to adjust for batch effect (details are described in the 
Supplementary materials).
Covariates
Using self-administered questionnaires and medical record data, we collected information of 
maternal age at enrollment, education level, race/ethnicity, smoking status, parity, pre-
pregnancy body mass index (BMI), last menstrual period; and children’s sex and birth 
weight. We estimated gestational age at delivery by subtracting the LMP date from the 
delivery date or by the ultrasound if the ultrasound estimation were available and differed 
from the LMP estimation by more than ten days. Based on U.S. national reference data 25, 
we calculated sex-specific birth weight-for-gestational age z-score using data on birth 
weight, gestational age, and child sex. We estimated the nucleated cell-type compositions 
(CD8 T-cells, CD4 T-cells, granulocytes, natural killer cells, B-cells, monocytes, and 
nucleated red blood cells) in the cord blood using a validated reference panel 26. We 
estimated the cell-type compositions (CD8 T-cells, CD4 T-cells, granulocytes, natural killer 
cells, B-cells and monocytes) in the children’s peripheral blood in mid-childhood using adult 
leukocyte reference panel for blood samples as implemented in minfi 27.
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Leptin and body composition measurements
We measured leptin concentration in cord blood and plasma of children’s blood in mid-
childhood using a radioimmunoassay (Linco Research Inc, St Charles, MO), as described 
previously 28. We used log-transformed leptin concentration and removed outliers. We 
included 235 cord blood samples and 225 children’s blood samples in our analyses. At mid-
childhood, we measured children’s height (cm), weight (kg), waist and hip circumferences 
(cm), subscapular (SS) and triceps (TR) skinfold thicknesses (mm), as described previously 
29
. We calculated age-sex-adjusted BMI z-score based on the U.S. national data 30, the sum 
of skinfold thicknesses (SS + TR) and waist-to-hip circumference ratios.
Statistical Analysis
We used mean [standard deviations (SD)], median (IQR) or percentages of covariates to 
describe characteristics of participants at birth and in mid-childhood. To test for individually 
differentially methylated CpG sites in relation to maternal CRH levels, we fit robust linear 
regression models for each CpG site on the M-value scale, adjusting for potential 
confounders including maternal age at enrollment, education, maternal race/ethnicity, 
maternal smoking status (never/former/current), pre-pregnancy BMI, parity, gestational age 
at delivery, child sex and cord blood cell-type estimation (CD8 T-cells, CD4 T-cells, natural 
killer cells, B-cells, monocytes, and nucleated red blood cells), using the MASS package in 
R. After inclusion of cell-type estimation and other potential confounders, the genomic 
inflation factor (λ) for the Epigenome-Wide Analysis was 1.03, indicating that results were 
unlikely driven by population stratification or cryptic relatedness (Figure S6). The statistical 
significance of the CpG-by-CpG analysis was evaluated using an FDR adjusted level (q < 
0.05). To ease biological interpretation, we presented the adjusted regression coefficient of 
maternal CRH on DNA methylation on the β-value scale. We also conducted a pathway 
analysis on the CpG sites passing the FDR using the ‘gometh’ function in ‘missMethyl’ 
package in R.
Subsequently, we performed a differentially methylated regional DNA methylation analysis 
using the DMRcate 31 package of R to examine the association between maternal CRH and 
differentially methylated regions (DMRs) in cord blood. We used a Gaussian kernel 
smoothing function to test statistics grouping significant CpG sites with bandwidth λ = 300 
base pairs and scaling factor C = 2. Significance testing among DMRs was adjusted for 
multiple comparisons using a Stouffer adjusted P < 0.05. We visualized the DMRs and their 
neighborhood regions using the coMET 32 in R.
Furthermore, we explored whether the associations of maternal CRH with differentially 
methylated CpG sites and regions in cord blood were persistent into mid-childhood using 
robust linear regression among our top candidate CpGs identified in our cord blood analyses. 
We regarded the mean methylation across all CpGs in the DMR as the regional methylation 
level, since the DNA methylation of CpGs in the DMR found in the present study were 
significantly correlated with each other. We adjusted robust linear regression models with 
maternal age at enrollment, education, maternal race/ethnicity, pre-pregnancy BMI, parity, 
child sex, cell-type estimations and the child’s age at blood collection for DNA methylation 
test. We considered associations statistically significant for persistence in childhood when 
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the P < 0.05 for the one region we had found in cord blood DMR analyses, and we used 
FDR to correct for number of CpG sites found in the cord blood CpG-by-CpG analyses.
Additionally, we performed two sensitivity analyses to test for bias caused by prenatal 
steroid treatments and preterm birth. All analyses were carried out using the R software, 
version 3.4.1.
Code availability
Code is available upon request.
Results
Characteristics of participants
Table 1 displays characteristics of mother-child pairs. In the participants included in the cord 
blood methylation analyses, the log2-transformed fully adjusted CRH levels ranged between 
4.3 – 9.7. Gestational age at blood draw for the CRH test ranged between 25 – 34 gestational 
weeks. In the primary analysis of mother-child pairs with cord blood DNA methylation, a 
majority of mothers were white (73%), multiparous (55%), never smoked (68%), and 
college graduate (67%). Characteristics of participants included in analyses of DNA 
methylation measured in mid-childhood were similar to those of participants included in the 
cord blood analyses.
Genome-wide CpG-by-CpG analysis in cord blood
In robust linear regression models for individual CpG sites, we found 96 differentially 
methylated CpG sites (FDR < 0.05) in cord blood relative to maternal CRH levels (Table 
S1). We showed the 7 CpG sites with the strongest associations that also reached Bonferroni 
adjusted significant level (P < 1.49 × 10−7) in Table 2. The percent changes in cord blood 
DNA methylation per doubling in maternal CRH concentration (adjusted regression 
coefficient) ranged between 0.09% - 1.74% among the top 7 CpG sites and between 0.03% - 
2.50% in absolute value among the overall 96 CpG sites. Among the 96 CpGs, cg12782180 
(P = 1.32× 10−08), cg00840332 (P = 1.24 × 10−07), cg19594666 (P = 3.82 ×10−07) were 
annotated to leptin (LEP) gene (region within <1500 base pairs from the transcription start 
site (TSS)), and had 1.74%, 0.81% and 1.86% increase in the DNA methylation levels in 
cord blood per doubling in maternal CRH concentration.
Among our top 7 differential CpG sites that reached Bonferroni adjusted significant level, 
we found 2 CpG sites annotated to LEP and the others were annotated to the following 5 
genes: ZNF428, LARGE, ARHGAP40, ADAMTS5, TGFA. At all 7 Bonferroni significant 
CpG sites, greater maternal CRH was associated with higher methylation levels (Figure 1). 
Similarly, methylation of the majority of 96 CpG sites (FDR < 0.05) were positively 
correlated with maternal CRH level, such as cg07380705 (CRHBP), cg16527491 (FOXA1), 
cg22937891 (TRIM36), cg13641043 (PLCD3), cg01078147 (SEMA6A), cg07891473 
(ADAMTS9), cg15558129 (LYPLAL1), and only eight show lower methylation levels 
associated with greater maternal CRH (Table S1).
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The sensitivity analyses show that our results were robust: effect sizes of associations 
between maternal CRH and methylation at all 96 FDR significant CpG sites were very 
similar in effect size and statistical significance values to our primary analyses after 
excluding subjects who had prenatal steroid treatment or were born at gestational age less 
than 37 weeks.
We conducted pathway analysis on the 96 CpGs passing FDR in the CpG-by-CpG analysis, 
but did not observe any GO pathways passing 5% FDR threshold. The top 10 GO terms 
were shown in Table S2.
Differentially Methylated Regions
In regional DNA methylation analysis, we detected one differentially methylated region 
(DMR) in relation to maternal CRH exposure (Stouffer adjusted P = 0.047). This region 
consists of 4 consecutive CpG sites (cg00840332, cg19594666, cg26814075, cg13381984) 
annotated to LEP gene on chromosome 7 (genomic coordinate: chr7:127881269–
127881344). This region includes two of the FDR-significant CpG sites (cg00840332, 
cg19594666) that we identified in CpG-by-CpG analysis. DNA methylation of each CpG 
site within the DMR of LEP was associated with 0.81% to 1.86% higher DNA methylation 
per doubling in maternal CRH concentration; the overall mean methylation of CpG sites 
across this region was 1.46% higher per doubling in maternal CRH level (P = 3.45 × 10−7) 
(Table 3). Figure 2 displays the P-value distribution of CpG sites in DMR of LEP gene and 
its neighborhood genomic region (upper panel), annotation of the region (middle panel) and 
the correlations among the CpG sites (lower panel). The methylation levels of the 4 CpG 
sites within the DMR of LEP were strongly and positively correlated with each other in cord 
blood cells (r = 0.65–0.90, P < 2.2×10−16) and mid-childhood blood cells (r = 0.66–0.91, P < 
2.2×10−16); thus, we used the mean methylation of the 4 CpG sites in subsequent analyses to 
represent the methylation level of this region. Figure S7 displays the DNA methylation of 
individual subjects for the 4 CpG sites in LEP region as well as the other 6 CpG sites 
passing the Bonferroni significant level in CpG-by-CpG analysis. In the sex-specific analysis 
(Table S3), the mean levels of DNA methylation at the LEP region in cord blood were 
similar in males and females; moreover, the associations between maternal CRH and LEP 
methylation were also significant in both females and males.
Persistence of associations in mid-childhood blood cell DNA methylation
In the analysis on persistence, we first focus our attention on the LEP methylation because 
we believe the association between maternal CRH and LEP methylation is the most robust 
among all CpGs. Multiple significant CpGs were detected in the LEP promoter region; 
moreover, the CRH-associated LEP methylation was verified by regional analysis. We 
evaluated the persistence of the association between maternal CRH and the DMR of LEP 
gene in the children’s blood samples in mid-childhood. The results were summarized in 
Table 3. The association between maternal CRH and DNA methylation at this DMR was 
attenuated at mid-childhood (mean methylation beta = 0.64% per doubling of maternal 
CRH; P=0.03), compared to cord blood associations (mean methylation beta= 1.46% per 
doubling of maternal CRH). In the sex-specific analysis (Table S3), mean levels of DNA 
methylation at the LEP region in mid-childhood were similar, and the associations between 
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maternal CRH and LEP methylation were significant in females but not in males. We 
additionally explored the persistence of the association in mid-childhood for the 96 
significant CpGs identified in cord blood. We found nominal associations between maternal 
CRH and mid-childhood blood methylation at 12 CpG sites (unadjusted P < 0.05), yet only 
cg25936177 (ACAN) remained significant after accounting for multiple testing (Table S4).
Associations among maternal CRH, LEP methylation, leptin levels, birth weight and body 
composition in mid-childhood.
Higher maternal CRH was associated with lower leptin concentration in cord blood (Table 
S5), but we did not observe an association between LEP methylation and leptin 
concentration, both measured in cord blood. Also, lower leptin level in cord blood was 
correlated with lower birth weight (Table S5) as expected, but we did not found that 
maternal CRH or LEP methylation were associated with birth weight (Table S5). In mid-
childhood, higher LEP methylation level in blood was associated with lower BMI z-score (β 
[se] = −3.11 [1.32], P = 0.02), log2-transformed skinfold thickness (β [se] = −1.92 [0.72], P 
= 0.01) and log2-transformed waist-hip ratio (β [se] = −0.18 [0.10], P = 0.07) (Table S6). 
The results indicated that one percent increase in LEP methylation was associated with 3.11 
decrease in BMI z-score, 3.84 times smaller in skinfold thickness and 0.36 times smaller in 
waist-hip ratio. We did not detect a significant association between LEP methylation and 
leptin concentration in blood at mid-childhood (β [se] = −2.72 [11.02], P = 0.80).
Discussion
In this pre-birth prospective cohort study, we found that higher maternal CRH concentration 
in mid-late pregnancy was associated with higher DNA methylation of CpG sites of the LEP 
gene by both individual CpG-by-CpG and regional analyses, and that this association 
persisted into mid-childhood. We also observed that maternal CRH was associated with 
DNA methylation levels at many other individual CpG sites for a total of 96 CpG sites, yet 
few of these seemed to persist later in childhood.
To our knowledge, this is the first study reporting associations between maternal CRH and 
LEP DNA methylation both at birth and persisting in mid-childhood in humans. Although 
no prior study has described this association, one study demonstrated that maternal 
dexamethasone (a type of synthetic glucocorticoids) treatment induced the programming of 
liver steatosis in offspring rats through increased LEP DNA methylation and the subsequent 
decreased leptin levels 33, which is in line with our finding. Additional findings from the 
same team demonstrated that rats prenatally overexposed to glucocorticoids had lower leptin 
levels in fetal plasmas and placenta 34,35. In a human study, mothers treated with 
betamethasone (a type of synthetic glucocorticoids) had offspring with lower leptin levels at 
birth 36. These studies support the association between high glucocorticoids exposure in 
pregnancy and lower circulating fetal leptin levels, as was the case of our observed positive 
correlation between maternal CRH and fetal LEP methylation and concordant with the 
known role of methylation down-regulating gene expression. The differentially methylated 
region of LEP found in our study was located in a CpG island, a CpG-rich region, within the 
proximal promoter region of LEP 37 containing many regulation elements of gene 
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expression. Although the present study could not directly address the function of 
methylation in this region on gene expression due to lack of RNA data, prior studies have 
documented the negative regulatory effect of DNA methylation level at this region on the 
LEP expression in human preadipocytes 37, subcutaneous adipose tissue 38, and placenta 
tissues 39. However, it was worth noting that we measured the DNA methylation of the white 
blood cells (WBCs) and use it as a proxy for other tissues that secrete leptin. The DNA 
methylation status of WBCs cannot fully represent the LEP DNA methylation in other 
tissues, such as adipose tissue. Circulating leptin in blood is mainly released from fat tissues 
and to a lesser extend from other tissues 40. Therefore, the blood LEP methylation may not 
be the most relevant tissue predicting leptin levels in the circulation. It could be one of the 
reasons why the association between LEP methylation and circulating leptin were not 
significant at both two-time points in the present study. Another reason is the complex 
regulation of gene transcription and protein translation. Due to lack of RNA data, we do not 
know either the association between LEP methylation and LEP expression or the association 
between LEP expression and leptin translation. Apart from DNA methylation, many other 
processes are involved in the regulation of gene transcription (e.g., non-coding RNA and 
histone modifications 41) as well as protein translation (e.g., global and gene-specific 
regulations 42). Such factors may influence associations between LEP methylation and leptin 
levels that were not captured in our study.
Leptin regulates feeding and energy balance by affecting hypothalamic function to balance 
food intake and body fat mass 43. Additionally, leptin serves broader roles during pregnancy. 
Studies found that lower leptin levels in cord blood were significantly correlated with lower 
birth weight-for-gestational age z-score4445, indicating the role of leptin in fetal growth. 
Moreover, the prior study of Project Viva found that lower cord blood leptin levels were 
associated with higher BMI at early childhood (3 years old) 46. The key roles of leptin in 
fetal growth and long-term development were also observed in LEP DNA methylation level. 
One study has found that the higher DNA methylation of LEP promoter in cord blood was 
associated with lower birth weight 47. However, we did not find significant association 
between LEP methylation and birth weight-for-gestational age z-score in the present study. 
This inconsistency may be attributed to our relatively small sample size or differences in the 
two populations including potential influence of genetic variation in LEP 47.
On average, the coefficients of prenatal CRH concentration on LEP DNA methylation is 
1.46% in cord blood and 0.64% in children’s blood, which are generally small effect sizes. 
Breton et al. have pointed out that small-magnitude effect sizes in DNA methylation are 
common, yet important in children’s environmental health studies 48. Although no prior 
study documented the effect size of prenatal CRH on LEP methylation, several studies 
commonly found small but significant changes in LEP methylation (generally on the scale of 
0.7%−2.3%) in relation to various exposures (e.g., prenatal PM2.5 exposure 49, folic acid 
supplement 50, duration of breastfeeding 51). To support the functional importance of 
relatively small differences in the DNA methylation of LEP, we explored the association 
between LEP methylation and the anthropometric measurements in mid-childhood and 
found every 1% increase in methylation at LEP, there was a 3.11 decrease in BMI z-score, 
3.84 times smaller in skinfold thickness and 0.36 times smaller in waist-hip ratio, which 
indicates that the small changes in methylation of LEP in relation to CRH can have strong 
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effects on biological activity. Consistent with our findings, other studies also identified the 
inverse relationship between methylation at LEP promoter and children obesity 52 or 
indicator of obesity 53. An animal study also suggested that diet-induced obese rats had 
lower LEP DNA methylation in blood 54.
Among other CpG sites that reached Bonferroni significant level, we found cg13523649 
(mean (SD) methylation level of 0.29 (0.04)) annotated to ARHGAP40 gene that encodes a 
Rho GTPase activating protein 40 involved in GTPase activator activity. Studies on 
ARHGAP40 gene are sparse, but the Rho GTPase activating protein family was found to be 
important in neuronal development 55. Interestingly, corticotropin-releasing factors modulate 
the brain neuronal morphology through Rho GTPases regulators in the process of stress 
response 56, which suggested a close relationship between Rho GTPase activating protein 
and corticotropin-releasing factors. These studies supported the association between 
maternal CRH and ARHGAP40 methylation present in our study.
Among other FDR-significant CpG sites where CRH was associated with cord blood DNA 
methylation, cg07380705 is annotated to Corticotropin-Releasing Hormone Binding Protein 
(CRHBP), which encodes a protein with important modulatory roles relative to CRH activity 
through binding with CRH and limiting the bioavailability of CRH 57. CRHBP is widely 
detected in human tissues including the placenta. Circulating plasma CRHBP in humans 
prevents inappropriate pituitary-adrenal stimulation caused by elevated plasma CRH during 
pregnancy 57. CRHBP is positively regulated by CRH concentration 58 as well as stress 
factors that are known to affect HPA axis activity 59. On epigenetics level, one study 
observed that maternal war trauma-related stress was associated with increased DNA 
methylation of one CRHBP CpG site (cg17448335) in placenta 60. This CpG site locates 
only 121bp upstream of cg07380705 that was found associated with maternal CRH levels in 
our present study. Moreover, the two CpG sites are all located within the same CpG island. 
Interestingly, CRHBP is not only involved in regulation of HPA axis activity through 
binding with CRH but also participates in mediating energy balance and metabolism through 
counteracting the thermogenic and anorectic actions of CRH 57. Our finding of CRHBP 
methylation changes supported the effect of maternal CRH on the energy metabolism of 
offspring. We also detected three CpG sites (cg16527491 FOXA1 61, cg22937891 TRIM36 
62
, cg13641043 PLCD363) annotated to the genes that are associated with blood pressure, 
and three CpG sites (cg01078147 SEMA6A 64, cg07891473 ADAMTS965, cg15558129 
LYPLAL165) annotated to the genes that are linked to body mass index and waist-hip ratio. 
PLCD3 (Phospholipase C Delta 3) encodes a member of the phospholipase C family, which 
are important in vascular smooth muscle signaling. One genome-wide association study 
(GWAS) has demonstrated that the common variants of PLCD3 were associated with 
systolic blood pressure 63. LYPLAL1 (Lysophospholipase Like 1) encodes a protein 
involved in the regulation of hydrolase activity and lysophospholipase activity. Multiple 
GWAS observed the common variants of LYPLAL1 associated with neonatal 
anthropometric measures 66, adult waist-hip ratio 65 and adiponectin levels 67. However, 
among the 96 CpGs, only one (cg25936177, ACAN) has persistent association with 
maternal CRH in mid-childhood. The lack of significant associations in mid-childhood could 
be explained by a few factors: first, some CpGs detected in cord blood with low variability 
may be false positive findings, according to Logue et al.’s study 68; second, the effect of 
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maternal CRH on fetal DNA methylation could be modified by many known and unknown 
factors between birth and mid-childhood. The effect on early life methylation may lead to 
changes at molecular, cellular, or tissue levels that persist through life, while the actual 
associations between prenatal exposure and methylation levels are not detectable because of 
additional modulations of methylation.
Among our strengths, this study prospectively evaluated the persistence of DNA methylation 
variabilities in childhood. In addition, this study is based on a well-characterized prospective 
cohort study, which enabled us to evaluate a large set of potential confounders. Furthermore, 
the regional analysis confirmed our CpG-by-CpG analyses. Lastly, we had the opportunity to 
analyze the potential influence of LEP DNA methylation on circulating leptin levels and 
anthropometric characteristics in the same dataset.
However, our study also had some important limitations. First, we only measured CRH level 
at one point in pregnancy, which may not comprehensively reflect maternal CRH level over 
the whole pregnancy and neglects the diurnal rhythm of CRH. In addition, we do not have 
data on gene expression measurements to assess the functionality of DNA methylation at the 
LEP locus; moreover, we do not have data on DNA methylation of tissues that 
predominantly secrete leptin, mainly adipose tissue. Many of our significant findings were at 
CpG sites with low (< 5%) or high (>95%) mean DNA methylation levels across all 
samples, which often indicated low variabilities with an increased risk of false positive 68. 
Moreover, we only pursued analyses of associations between maternal CRH and DNA 
methylation in mid-childhood blood for the CpG sites we had identified at birth; we 
acknowledge that other signals may emerge later in life but are not detectable in cord blood.
Conclusion
This study adds to the growing body of evidence showing that glucocorticoid exposure in 
pregnancy is associated with children’s health programming. Variations in DNA methylation 
levels of LEP promoter observed at birth might provide a potential explanation for the short- 
and long-term health effects of prenatal glucocorticoid exposure in offspring.
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Figure 1. 
Scatterplots for the associations between differentially methylated CpGs (Bonferroni p < 
1.49 ×10−7) and maternal corticotropin-releasing hormone level (log2-transformed CRH 
corrected for technician and gestational age at CRH test) during pregnancy. The red 
regression line was fitted with simple linear regression. The blue was non-parametric 
regression line with locally weighted smoothing. The Pearson correlation coefficient of each 
CpG site resulted from partial correlation analysis adjusted for maternal age, education, 
maternal race/ethnicity, gestational age, pre-pregnancy BMI, parity, child sex and cell-type 
estimations.
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Figure 2. 
Regional plot of the LEP gene DMR and its neighborhood area. The upper panel shows the 
P values of CpGs methylation in the epigenome-wide association with maternal CRH. The 
middle panel provides the annotation tracks, including ENSEMBL Genes, CpG islands 
tracked from UCSC, DNase cluster tracked from UCSC, SNPs tracked from UCSC. The 
lower panel shows the correlation of methylation among the CpGs in this selected region. 
The CpG sites in the differentially methylated region (DMR) of LEP gene was marked.
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Table 1.
Characteristics of mothers and children included in analyses at birth and in mid-childhood.
Characteristics
Cord blood Middle childhood
N = 257 N = 239
Mothers
Maternal age at enrollment, years: Mean (SD) 32.1 (5.3) 32.2 (5.3)
Pre-pregnancy BMI, kg/m2: Mean (SD) 24.4 (4.9) 24.7 (5.3)
Mothers’ race/ethnicity: N (%)
    . White 189 (73) 162 (68)
    . Black 29 (11) 41 (17)
    . Hispanic 21 (8) 15 (6)
    . Other 18 (7) 21 (9)
Nulliparous: N (%) 115 (45) 106 (44)
>= College graduate: N (%) 173 (67) 166 (70)
Smoking status: N (%)
    . Never 176 (68) 169 (71)
    . During pregnancy 26 (10) 24 (10)
    . Former 55 (21) 46 (19)
Log2-transformed CRH corrected for technician and gestational age at CRH test, Mean (SD) 7.1 (0.8) 7.1 (0.9)
Gestational age at CRH test, weeks: Mean (SD) 27.9 (1.3) 27.9 (1.7)
Children
Gestational age at delivery, weeks: Mean (SD) 39.7 (1.3) 39.6 (1.4)
Birth weight, g: Mean (SD) 3559.1 (514.4) 3554.3 (528.4)
Birth weight (z-score)a: Mean (SD) 0.3 (1.0) 0.3 (1.0)
Age at blood samples collection
    . At birth (gestational age in weeks) 39.7 (1.3) -
    . In middle childhood (6.7 to 10.3 years) - 7.9 (0.8)
Female: N (%) 126 (49) 115 (48)
Children’s race/ethnicity: N (%)
    . White 178 (69) 153 (64)
    . Black 34 (13) 45 (19)
    . Hispanic 14 (5) 11 (5)
    . Other 31 (12) 30 (13)
BMI z-score: Mean (SD), n = 236 - 0.40 (1.3)
Skinfold thickness (mm): Median (IQR), n = 236 - 16.4 (8.7)
Waist-hip ratio: Median (IQR), n = 237 - 0.9 (0.1)
BMI, body mass index. CRH, corticotropin-releasing hormone.
a
Birth weight adjusted for gestational age and child sex using U.S. national reference
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Table 2.
CpG sites with differential DNA methylation at birth (257 cord blood samples) in relation to maternal CRH 
level during pregnancy (reaching P < 1.49 × 10−7).
CpGs Mean (SD) β-Coefficient (SE)a % P b FDR b Position c Island c Gene c Region c
cg26180126 0.01 (0.00) 0.09 (0.02) 1.43 × 10−7 0.01 chr2: 70779764 N_Shore TGFA Body
cg12782180 0.28 (0.06) 1.74 (0.31) 1.32 × 10−8 1.47 × 10−3 chr7: 127880932 Island LEP TSS1500
cg00840332 0.05 (0.03) 0.81 (0.17) 1.24 × 10−7 0.01 chr7: 127881269 Island LEP TSS200
cg18656583 0.02 (0.00) 0.14 (0.02) 1.37 × 10−10 4.57 × 10−5 chr19: 44124056 Island ZNF428 TSS200
cg13523649 0.29 (0.04) 1.42 (0.26) 8.79 × 10−8 0.01 chr20: 37230741 Island ARHGAP40 Body
cg13601496 0.02 (0.00) 0.15 (0.03) 1.20 × 10−7 0.01 chr21: 28339487 Island ADAMTS5 TSS200
cg21028171 0.03 (0.01) 0.19 (0.03) 8.73 × 10−10 1.46 × 10−4 chr22: 34316977 Island LARGE TSS1500
Chr, chromosome; UTR, untranslated region; TSS, transcription start site. SD, standard deviation. SE, standard error of coefficient.
a
The coefficients are estimated according to the robust linear regression on beta value scale, adjusted for maternal age at enrollment, maternal 
education level, maternal race, maternal smoking status, pre-pregnant BMI, parity, gestational age at delivery, child sex, and the estimated 
proportions of CD8 T-cell, CD4 T-cell, natural killer cells, B-cells, monocytes, and red blood cells in cord blood. The coefficient of each CpG site 
represents the percent change in cord blood DNA methylation in relation to per doubling increased maternal CRH level during pregnancy.
b
The P values and FDRs are estimated according to the robust linear regression on M-value scale, adjusted for the same covariates with the model 
on beta value scale.
c
The annotation information are according to the R package of “IlluminaHumanMethylation450kanno.ilmn12.hg19”.
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Table 3.
DNA methylation of CpG sites in the differentially methylated region of LEP (chr7:127880932–127881440) at 
birth (cord blood) and at mid–childhood (blood) in relation to maternal CRH level during pregnancy.
CpG Position Region Island
At birth (cord blood) (N = 257) Mid-childhood (N = 239)
β-Coefficient (SE)a % P b β-Coefficient (SE)a % P b
    Mean DNA methylation of this region 1.46 (0.29) 3.45 × 10−7 0.64 (0.30) 0.03
cg00840332 127881269 TSS200 island 0.81 (0.17) 1.24 × 10−7 0.55 (0.24) 0.02
cg19594666 127881280 TSS200 island 1.86 (0.38) 3.82 × 10−7 0.70 (0.43) 0.10
cg26814075 127881298 TSS200 island 1.51 (0.38) 7.29 × 10−5 0.66 (0.35) 0.06
cg13381984 127881344 1stExon island 1.48 (0.38) 1.28 × 10−4 0.71 (0.34) 0.03
TSS, transcription start site. SD, standard deviation. SE, standard error of coefficient.
a
The coefficients are estimated according to the robust linear regression on beta value scale, adjusted for maternal age at enrollment, maternal 
education level, maternal race, maternal smoking status, pre-pregnant BMI, parity, gestational age at delivery, child sex, and the estimated 
proportions of CD8 T-cell, CD4 T-cell, natural killer cells, B-cells, monocytes, and red blood cells (cord blood only), age of children in years at the 
time of the blood draw for DNA methylation test (childhood only). The coefficient of each CpG site represents the percent change in DNA 
methylation in relation to per doubling increased maternal CRH level during pregnancy.
b
The P values are estimated according to the robust linear regression on M-value scale, adjusted for the same covariates with the model on beta 
value scale.
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